Liquidia Corporation (LQDA) |
| 40.27 1.56 (4.03%) 04-15 13:32 |
| Open: | 38.92 |
| High: | 40.4 |
| Low: | 38.92 |
| Volume: | 327,115 |
| Market Cap: | 3,548(M) |
| PE Ratio: | -50.34 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 47.61 |
| Resistance 1: | 40.76 |
| Pivot price: | 37.75 |
| Support 1: | 36.71 |
| Support 2: | 34.21 |
| 52w High: | 46.67 |
| 52w Low: | 11.85 |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Financials
| EPS | -50350000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 97.500 |
| Profit Margin (%) | -43.54 |
| Operating Margin (%) | 21.50 |
| Return on Assets (ttm) | -11.5 |
| Return on Equity (ttm) | -111.1 |
Company news
Wed, 15 Apr 2026
Wall Street analysts see a 35.35% upside in Liquidia Corporation (LQDA): Can the stock really move this high? - MSN
Tue, 14 Apr 2026
Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells 9,220 Shares of Stock - MarketBeat
Tue, 14 Apr 2026
Liquidia (NASDAQ:LQDA) CEO Sells $859,891.96 in Stock - MarketBeat
Tue, 14 Apr 2026
Michael Kaseta Sells 18,958 Shares of Liquidia (NASDAQ:LQDA) Stock - MarketBeat
Tue, 14 Apr 2026
Liquidia (NASDAQ:LQDA) CFO Sells 23,821 Shares - MarketBeat
Tue, 14 Apr 2026
Liquidia corp (LQDA) CBO Adair sells $280k in shares - Investing.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
